Abstract: Systems, methods, and computer-readable storage media for generating, transmitting, and utilizing a composite radar and communication waveform are disclosed. The composite radar and communication waveform may facilitate radar detection and data communication operations and may be generated from a frequency modulated (FM) radar waveform and a communication signal. In an aspect, the composite radar and communication waveform may be generated by iteratively executing a shaping process against the FM radar waveform and the communication signal until a first stop criterion is satisfied to produce an initial composite radar and communication waveform having the communication signal embedded therein, and then iteratively executing an enhancement process against the initial composite radar waveform and the communication signal until a second stop criterion is satisfied to produce a final composite radar and communication waveform suitable for both radar detection and data communication operations.

Abstract: Vectors having a nucleotide sequence having SEQ ID NO:1 or a nucleotide sequence having at least 85% identity to SEQ ID NO:1, or a portion thereof, that is capable of regulating bocaparvovirus replication, or vectors having the complement of the nucleotide sequence, and methods of using the vectors, are provided.

Abstract: A multipurpose front-end board for solid state sensors is described. In particular, the board is optimized for fast timing particle detection or for characterization and test of silicon and diamond detectors that produce a fast but small current signal at the passage of a particle. The multipurpose front-end board includes a sensor pad configured to receive a solid state sensor to be characterized, distribute a bias potential, and read out the current signal produced by the sensor. The board also includes an amplifier configured to read out the current signal from the sensor pad and convert the current signal to an output voltage signal and a discriminator configured to receive the output voltage signal from the amplifier. A threshold voltage of the discriminator can be controlled by a potentiometer, and the board includes at least one output port to provide data for characterization of the sensor.

Abstract: A non-human organism for upgrading intermediate oxidation products formed by catalytic degradation of alkanes or polystyrenes is provided. The non-human organism is genetically modified to convert the intermediate oxidation products to secondary metabolites, and in particular to include a positive feedback loop construction in the promotor system. A method includes steps of catalytically degrading alkanes or polystyrene in an oxidizing environment to form intermediate products with one or more catalysts and contacting the intermediate products with the non-human organism such that intermediate oxidation products are converted to secondary metabolites.

Abstract: An approach for fatigue crack detection is described. In one example, a first image of a structure is captured at a first time, and a second image of the structure is captured at a second time. A feature-based image registration is performed to align features of the second image with the first image, and an intensity-based image registration is performed to further align features of the second image with the first image. A registration error map is determined by performing a pixel-by-pixel intensity comparison of the first image and the second image. Additionally, an edge-aware noise reduction process can be performed on the registration error map. The registration error map can be referenced to identify certain fatigue cracks in the structure.

Abstract: Compounds, compositions, and methods related to bioenergetic metabolism are provided. The compounds and compositions are suited to promote bioenergetic processes including cellular respiration and glycolytic flux and may be used to treat mitochondrial disorders, neurodegenerative diseases (such as Alzheimer's disease (AD), Parkinson's disease, and/or amyotrophic lateral sclerosis), multiple sclerosis, and/or epilepsy.

Abstract: The present technology provides compounds according to Formula I or Formula III as well as compositions including such compounds useful for the treatment of metastatic cancer and/or glaucoma.

Abstract: Disclosed herein are compounds and methods for inhibiting Aha1 for the treatment of tauopathies and neurodegenerative diseases. The Aha1 inhibitor may reduce the interaction between Aha1 and Hsp90. The Aha1 inhibitor may reduce aggregation of tau protein. The Aha1 inhibitor may include a compound selected from KU-177, KU-174, and KU-308.

Abstract: Provided are processes for producing metal oxides, including pigmentary TiO2. In embodiments, a process for producing a metal oxide comprises combining a metal halide and an oxidant in a liquid phase medium under conditions to oxidize the metal halide in the liquid phase medium to produce a metal oxide therefrom.

Abstract: Disclosed are functional materials for use in additive manufacturing (AM). The functional material can comprise an elastomeric composition (e.g., a silicone composite) for use in, for example, direct ink writing. The elastomeric composition can include an elastomeric resin, and a magnetic nanorod filler dispersed within the elastomeric resin. Nanorod characteristics (e.g., length, diameter, aspect ratio) can be selected to create 3D-printed constructs with desired mechanical properties along different axes. Furthermore, since nickel nanorods are ferromagnetic, the spatial distribution and orientation of nanorods within the continuous phase can be controlled with an external magnetic field. This level of control over the nanostructure of the material system offers another degree of freedom in the design of functional parts and components with anisotropic properties. Magnetic fields can be used to remotely sense compression of the constructs, or alternatively, control the stiffness of these materials.

Abstract: The present technology relates to compounds of any one of Formula I, II, IIa, III, IV, and/or V as described herein and their tautomers and/or pharmaceutically acceptable salts, compositions, and methods of uses thereof.

Abstract: The present application relates to stacked piezoelectric composites comprising piezoelectric structures. Suitably, the composites are useful as tissue-stimulating implants, including spinal fusion implants. The present application also relates to methods of making stacked piezoelectric composites.

Abstract: A method of making a plasmonic metal/graphene heterostructure comprises heating an organometallic complex precursor comprising a metal at a first temperature T1 for a first period of time t1 to deposit a layer of the metal on a surface of a heated substrate, the heated substrate in fluid communication with the precursor; and heating, in situ, the precursor at a second temperature T2 for a second period of time t2 to simultaneously form on the layer of the metal, a monolayer of graphene and a plurality of carbon-encapsulated metal nanostructures comprising the metal, thereby providing the plasmonic metal/graphene heterostructure. The heated substrate is characterized by a third temperature T3. The plasmonic metal/graphene heterostructures, devices incorporating the heterostructures, and methods of using the heterostructures are also provided.

Abstract: Methods for producing engineered exosomes and other vesicle-like biological targets, including allowing a target vesicle-like structure to react and bind with immunomagnetic particles; capturing the immunomagnetic particle/vesicle complex by applying a magnetic field; further engineering the captured vesicles by surface modifying with additional active moieties or internally loading with active agents; and releasing the engineered vesicle-like structures, such as by photolytically cleaving a linkage between the particle and engineered vesicle-like structures, thereby releasing intact vesicle-like structures which can act as delivery vehicles for therapeutic treatments.

Abstract: The disclosure is directed to methods and compositions delaying the gelation of polymers in water flooding by sequentially or co-injecting a carboxylate-containing polymer solution, a gel-delaying polymer, and gelation agent into a hydrocarbon reservoir. Delays of weeks are observed.

Abstract: The present application discloses a new form of ?-STAP, referred to herein as post ?-STAP or P?-STAP, which overcomes the drawbacks associated with existing ?-STAP techniques. The P?-STAP techniques described herein facilitate the generation of additional training data and homogenization after pulse compression. For example, P?-STAP techniques may apply a plurality of homogenization filters to a pulse compressed datacube generated from an input radar waveform, which produces a plurality of new pulse compressed datacubes with improved characteristics. Unlike existing ?-STAP techniques described above, which require pre-pulse compressed data to operate, the P?-STAP techniques disclosed in the present application are designed to utilize pulse compressed data, and therefore may be readily applied to legacy radar systems.

Abstract: An aeromechanically stable sabot system that includes a center of gravity that is placed forward of an aerodynamic center of the aeromechanically stable sabot system when in steady-state flight. By placing the center of gravity forwards of the aerodynamic center, the sabot system exhibits positive longitudinal and directional stability. To illustrate, the sabot system and/or portions thereof will return to stable flight after being disturbed in pitch (vertically or about a transverse horizontal axis) or yaw (side to side or about a vertical axis) when traveling horizontally.

Abstract: A method of treating and/or preventing Rift Valley fever, comprising administering an effective amount of a compound of formula (I), formula (II), formula (III), formula (IV), formula (V), formula (VI), formula (VII) or formula (VIII), or a salt thereof, to a subject need thereof; a pharmaceutical composition comprising a compound of formula (I), formula (II), formula (III), formula (IV), formula (V), formula (VI), formula (VII) or formula (VIII), or a salt thereof, and a pharmaceutically acceptable carrier; and a pharmaceutical composition comprising a compound selected from the group consisting of compound WMA-RV1, compound WMA-RV2, compound MA-RV3, compound WMA-RV4, compound WMA-RV5, compound WMA-RV6, compound WMA-RV7, or compound WMA-RV8, or a salt thereof, and a pharmaceutically acceptable carrier.

Abstract: The present technology provides compounds of Formula I (or pharmaceutically acceptable salts and/or solvates thereof) that are useful in treating a CNS-related disorder such as schizophrenia, schizoaffective disorder, migraine, depression, pain, drug addiction, drug use, and/or drug seeking behavior. Also provided are compositions, medicaments, and methods including such compounds.

Abstract: The instant application relates to nanogels or compositions that hold multivalent metal ions until some level of nanogel degradation has occurred, then slowly release the multivalent metal ions for gelation with carboxylate containing polymers. Compositions comprising such nanogels, together with polymers that can be crosslinked with multivalent metal ions, allow the deployment of such mixtures in various applications, and greatly increased gelation times.